This trial is active, not recruiting.

Condition prostate cancer
Treatment whole-mount sectioning of the prostate
Sponsor University Health Network, Toronto
Start date June 2008
End date June 2017
Trial size 16 participants
Trial identifier NCT00791115, NIH CA12156, UHN REB 08-0350-CE


The purpose of this study is to compare the location of the cancer found in the prostate gland after it is removed to the location that was predicted on the MRI scan during biopsy. In this way, we can better determine if the Magnetic Resonance Imaging (MRI) was accurate, and if the MRI could be safely used to guide other types of treatments such as brachytherapy. We also plan to carefully measure how frequently surgery is able to completely remove the cancer, as well as the side effects and effectiveness of surgery after radiotherapy. The study will be coordinated and closely integrated with a separate concurrent study of MRI-guided prostate biopsy, which will be performed prior to accrual to this trial (UHN 05-0641-C).

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Intervention model single group assignment
Masking open label
Primary purpose treatment
whole-mount sectioning of the prostate
A standard open retropubic radical prostatectomy will be performed. Whole fresh prostate is be embedded in gel and oriented in the anatomic position in a plastic cylinder using wood skewers. Standard pathology reports are generated from this tissue

Primary Outcomes

To Validate virtual dosimetry plans for tumor-targeted salvage (High-Dose-Rate) HDR brachytherapy against co-registered whole-mount prostatectomy specimens.
time frame: Patients will have follow-up assessments at 1,3 and 6 months and 1,2,3 and 5 years after surgery.

Secondary Outcomes

Preliminary evaluation of surgical margin status, toxicity and QOL, and biochemical control after salvage RP.
time frame: Patients will have follow-up assessments at 1,3 and 6 months and 1,2,3 and 5 years after surgery.

Eligibility Criteria

Male participants at least 18 years old.

Inclusion Criteria: - Prior enrollment of UHN 05-0641-C - Histological evidence of cancer on MRI-guided prostate biopsy - PSA doubling time > 6 months - ECOG 0 or 1 - All patients must give written informed consent indicating their understanding of the investigational nature and risks of the study before any protocol related studies are performed Exclusion Criteria: - Contraindications to salvage prostatectomy - Previous rectal surgery for IBD or cancer such that an ileo-anal anastomosis is present. - Radiological evidence of regional or distant metastases

Additional Information

Official title Salvage Prostatectomy After Radiotherapy: Whole-Mount Histopathological Validation for Tumor-Targeted Salvage HDR Brachytherapy
Principal investigator Cynthia Ménard, MD
Description Two hundred and nineteen thousand new cases of prostate cancer have been projected in the Unites States for 2007, with external beam radiotherapy (EBRT) constituting the mainstay of local therapy for an increasing proportion of newly diagnosed patients. Despite improvements in the delivery and reduction in associated toxicity of external beam radiotherapy, local persistence or recurrence of disease remains prevalent in 25-51% of patients. Local disease after EBRT is a risk factor for subsequent metastatic progression and prostate cancer-specific mortality, and is a cause of morbidity including hematuria, obstructive uropathy, and chronic pain. Given its prevalence, and the lack of satisfactory local salvage treatments, fear of prostate cancer recurrence has been shown to impose a substantial burden of suffering in patients. Stereotactic needle placement under MRI-guidance enables two critical steps in tumor-targeted brachytherapy: 1) directly guiding brachytherapy catheters to sites of tumor recurrence, and 2) permitting treatment planning and delivery to be based on 3D MRI images. MRI-based HDR brachytherapy will precisely identify the location of brachytherapy catheters relative to the target volumes and adjacent normal structures at risk of radiation injury, obviating the need for invasive saturation (24-100) mapping biopsies. This study will build the evidence supporting the concept of tumor-targeted salvage HDR brachytherapy, by providing further histopathological validation of the method.
Trial information was received from ClinicalTrials.gov and was last updated in June 2016.
Information provided to ClinicalTrials.gov by University Health Network, Toronto.